Long-term pegylated interferon-α and its potential in the treatment of melanoma

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 169-182

  Dummer, Reinhard ^a   Mangana, Joanna ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Interferons; Melanoma; Pegylated interferon

Indexed keywords

EID: 77954327720     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S4169     Document Type: Review

References (122)

1. Isaacs A, Lindenmann J. Virus Interference. I The interferon. Proc R Soc. London Ser B. 1957;147:258.
2. Kerr IM, Stark GR. The antiviral effects of the interferons and their inhibition. J Interferon Res. 1992;12:237-240.
3. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778-809.
4. Sen GC, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem. 1992;267:5017-5020.
5. Nathan C. Interferon and inflammation. In: Gallin JI, Goldstein IM, Schnyder R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press; 1992. p. 265-290.
6. Beattie E, Tartaglia J, Paoletti. E. Vaccinia virus-encoded elF-2a homolog abbrogates the anitiviral effect of interferon. Virology. 1991;183:419-422.
7. Bandyopadhyay S, Perussia B, Trinchieri G, et al. Requirement for HLA-DRHHaccessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med. 1986;164:180-195.
8. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835-1837.
9. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919-923.
10. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219-1226.
11. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005;79:17-27.
12. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987-995.
13. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190:1417-1426.
14. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003;200:255-268.
15. Liu C, Lou Y, Lizee G, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118:1165-1175.
16. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem. 1987;56:727-777.
17. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95:7556-7561.
18. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6:722-729.
19. Paredes J, Krown SE. Interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Int J Immunopharmacol. 1991;(13 Suppl 1):77-81.
20. Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons. Mechanisms of action and clinical applications. Jama. 1991;266:1375-1383.
21. Borden EC: Interferons in JF Holland, Frei III, JR Bast, DW Kufe, DL. Morton and RR Wechselbaum (eds). Cancer Medicine MD: Wiliams and Wilkins. 1997;1119-1212.
22. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 1994;91:1198-1205.
23. Buzaid AC, Robertone A, Kisala C, et al. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol. 1987;5:1083-1089.
24. Krown SE. Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987;59:647-651.
25. Interferon Nomenclature. Nature. 1980;286:110.
26. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375-386.
27. Pestka S. The human interferon-alpha species and hybrid proteins. Semin Oncol. 1997;24:S9-4, S9-17.
28. LaFleur DW, Nardelli B, Tsareva T, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001;276:39765-39771.
29. Conklin D, Grant F, Rixon M, et al. Interferon-epsilon. US Patent. 2002;6329175.
30. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69-77.
31. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8-32.
32. Pestka S. The human interferon alpha species and receptors. Biopolymers. 2000;55:254-287.
33. Weissmann C, Nagata S, Boll W, et al. Structure and expression of human IFN-alpha genes. Philos Trans R Soc Lond B Biol Sci. 1982;299:7-28.
34. Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol. 1998;25:9-13.
35. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002; 58:169-178.
36. Weinstock-Guttman B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs. 2000;59:401-410.
37. Domanski P, Colamonici OR. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 1996;7:143-151.
38. Schindler C, Shuai K, Prezioso VR, et al. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science. 1992;257:809-813.
39. Fu XY, Schindler C, Improta T, et al. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci U S A. 1992;89:7840-7843.
40. Shuai K, Schindler C, Prezioso VR, et al. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science. 1992;258:1808-1812.
41. Chen J, Baig E, Fish NE. Diversity and relatedness among the type I interferons. J Interfon Cytokine Res. 2004;24:687-9-698.
42. Darnell JE, Jr. Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.
43. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol. 1995;60:1-35.
44. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003;15:431-439.
45. Horvath CM, Darnell JE Jr. The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein. J Virol. 1996;70:647-650.
46. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
47. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653-1655.
48. Meinke A, Barahmand-Pour F, Wohrl S, et al. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol. 1996;16:6937-6944.
49. Farrar JD, Smith JD, Murphy TL, et al. Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. J Biol Chem. 2000;275:2693-2697.
50. Torpey N, Maher SE, Bothwell AL, et al. Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells. J Biol Chem. 2004;279:26789-267896.
51. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93:1980-19891.
52. Fasler-Kan E, Pansky A, Wiederkehr M, et al. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem. 1998;254:514-519.
53. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem. 1999;274:30127-30131.
54. Goh KC, Haque SJ, Williams BR. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 1999;18:5601-5608.
55. Li Y, Sassano A, Majchrzak B, et al. Role of p38a Map kinase in type I interferon signaling. J Biol Chem. 2004;279:970-979.
56. Uddin S, Yenush L, Sun XJ, et al. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. J Biol Chem. 1995;270:15938-15941
57. Ahmad S, Alsayed YM, Druker BJ, et al. The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. J Biol Chem. 1997;272:29991-29994.
58. Roberts RM, Ealy AD, Alexenko AP, et al. Trophoblast interferons. Placenta. 1999;20:259-264.
59. Bazer FW, Spencer TE, Ott TL. Interferon tau: a novel pregnancy recognition signal. Am J Reprod Immunol. 1997;37:412-420.
60. Chen J, Wood W. Interferon PRO655. Genentech. [US 6,300,475] (Patent). 2003;1-37.
61. Ealick SE, Cook WJ, Vijay-Kumar S, et al. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991;252:698-702.
62. Carnaud C, Lee D, Donnars O, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163:4647-4650.
63. Frucht DM, Fukao T, Bogdan C, et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001;22:556-560.
64. Flaishon L, Hershkoviz R, Lantner F, et al. Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med. 2000;192:1381-1388.
65. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1:475-482.
66. Perussia B, Kobayashi M, Rossi ME, et al. Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J Immunol. 1987;138:765-774.
67. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163-189.
68. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997;15:563-591.
69. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-264.
70. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferongamma. Annu Rev Immunol. 1997;15:749-795.
71. Dummer R, Cozzio A, Urosevic M. Interferons in cutaneous T-cell Lymphomas. Hematologica Reports. 2006;2(13):71-74.
72. Roferon Drug Information: Roche Laboratories; Nutley, NJ.
73. Cada D, Convington T, et al. Drug Facts and Comparisons. St. Louis Misouri:Facts and Comparisons, Inc. 2000;1571-1580.
74. Creasey AA, Eppstein DA, Marsh YV, et al. Growth regulation of melanoma cells by interferon and (2'-5')oligoadenylate synthetase. Mol Cell Biol. 1983;3:780-786.
75. Buzaid AC, Grimm EA, Ali-Osman F, et al. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res. 1994;4:327-330.
76. Anderson CM, Buzaid AC, Sussman J, et al. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 1998;8:149-155.
77. Bernengo MG, Quaglino P, Cappello N, et al. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res. 2000;10:55-65.
78. Haller O, Arnheiter H, Lindenmann J, et al. Host gene influences sensitivity to interferon action selectively for influenza virus. Nature. 1980;283:660-662.
79. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559-568.
80. Aebi M, Fah J, Hurt N, et al. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol. 1989;9:5062-5072.
81. Horisberger MA, McMaster GK, Zeller H, et al. Cloning and sequence analyses of cDNAs for interferon-and virus-induced human Mx proteins reveal that they contain putative guanine nucleotide-binding sites: functional study of the corresponding gene promoter. J Virol. 1990;64:1171-1181.
82. Holzinger D, Jorns C, Stertz S, et al. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol. 2007;81:7776-7785.
83. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferonbeta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler. 2006;12:47-57.
84. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic. 2002;3:710-7.
85. Jakschies D, Hochkeppel HK, Horisberger MA, et al. Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma. J Invest Dermatol. 1990;95:238S-241S.
86. Ralph SJ, Wines BD, Payne MJ, et al. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J Immunol. 1995;154:2248-2256.
87. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferonalpha2b. Clin Cancer Res. 2007;13:2422-2428.
88. Critchley-Thorne RJ, Yan N, Nacu S, et al. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007;4:e176.
89. Takahashi Y, Kaneda H, Takasuka N, et al. Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci. 2008;99:1650-1655.
90. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 2002;13:413-421.
91. Sakai I, Takeuchi K, Yamauchi H, et al. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood. 2002;100:2926-2931.
92. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718.
93. Nordlung J, Kirkwood J, Milton BFG, et al. Vitiligo in patients with metastastic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;689-696. Abstract.
94. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23 Suppl 1:23-8.
95. Wang YS, Youngster S, Bausch J, et al. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000;39:10634-10640.
96. PEG-Intron: Drug Information, Schering Corporation.
97. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology. 2000;32: 647-653.
98. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
99. Peg-INFa-2a, Pegasys: Drug Information. www.rocheusa.com/ products/pegasys/pi.pdf.
100. Algrananti N, Sy S, Mobi M. A branched methoxy 40 kDa polyethylene glykol (PEG) moiety optimizes the pharmakocinetics (PK) of peginterferon a-2a(PEG-IFN)and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology. 1999;190A: Abstract.
101. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
102. Dummer R, Panizzon R, Bloch PH, et al. Updated Swiss guidelines for the treatment and follow up of cutaneous melanoma. Dermatology. 2005;39-44.
103. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
104. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-167.
105. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189-1196.
106. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
107. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-126.
108. Dummer R, Garbe C, Thompson JA, et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol. 2006;24:1188-1194.
109. Millwald MJ, Bedikian AY, Conry RM, et al. Randomized multinational phase III trial of dacarbazine(DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advnced maligannt melanoma (MM). Analysis of long-term survival. ASCO Annual Meeting: Abstract Nr. 2004;7505.
110. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-570.
111. Kurokohchi K, Takaguchi K, Kita K, et al. Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. World J Gastroenterol. 2005;11:5401-5403.
112. Son MJ, Song HS, Kim MH, et al. Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma. Int J Oncol. 2006;28:1385-1392.
113. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001-9007.
114. Hwu WJ, Panageas KS, Menell JH, et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006;106:2445-51.
115. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-66.
116. Spieth K, Kaufmann R, Dummer R, et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol. 2008;19:801-6.
117. Hauschild A, Dummer R, Ugurel S, et al. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer. 2008;113:1404-11.
118. Vaishampayan UN, Heilbrun LK, Marsack C, et al. Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs. 2007;18:1221-6.
119. Medwatch. What is a serious adverse effect? www.fda.gov retrieved on 2007;09-18.
120. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008;112:982-94.
121. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001;92:1664-8.
122. Arzneimittel-Kompendium der Schweiz http://www.kompendium.ch/ Copyright by Documed AG, Basel, Switzerland 2008.